AstraZeneca India receives permission from DCGI for Dapagliflozin
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Subscribe To Our Newsletter & Stay Updated